Ellen Duong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ellen Duong has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Stefani Spranger
Koch Institute for Integrative Cancer Research, Massachusetts Institute for Technology, Cambridge, MA, USA
32 shared publications - Leon Yim
Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts
31 shared publications - Charles A. Whittaker
The David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA
30 shared publications - Elen Torres-Mejia
Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts
30 shared publications - Kim Bich Nguyen
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
30 shared publications - Sally Weng
Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts
30 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S1 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S1 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S3 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S3 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S4 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S4 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S2 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion
Table S2 from Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg‐Dependent CD8+ T-cell Exclusion